DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03713892 (ClinicalTrials.gov)	May 23, 2018	17/10/2018	CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects	Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects	Huntington Disease	Drug: CKD-504;Drug: Placebo	Chong Kun Dang Pharmaceutical	NULL	Recruiting	19 Years	45 Years	All	88	Phase 1	Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03713892
(ClinicalTrials.gov)

May 23, 2018

17/10/2018

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Huntington Disease

Drug: CKD-504;Drug: Placebo

Chong Kun Dang Pharmaceutical

NULL

Recruiting

19 Years

45 Years

All

Phase 1

Korea, Republic of